HK1249033A1 - 用於治療細菌感染的殺菌劑與親溶酶體鹼化劑的組合 - Google Patents

用於治療細菌感染的殺菌劑與親溶酶體鹼化劑的組合

Info

Publication number
HK1249033A1
HK1249033A1 HK18108776.3A HK18108776A HK1249033A1 HK 1249033 A1 HK1249033 A1 HK 1249033A1 HK 18108776 A HK18108776 A HK 18108776A HK 1249033 A1 HK1249033 A1 HK 1249033A1
Authority
HK
Hong Kong
Prior art keywords
agent
lysosomotropic
treatment
combination
bacterial infection
Prior art date
Application number
HK18108776.3A
Other languages
English (en)
Inventor
Eichenseher Fritz
Original Assignee
Micreos Human Health Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micreos Human Health Bv filed Critical Micreos Human Health Bv
Publication of HK1249033A1 publication Critical patent/HK1249033A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18108776.3A 2015-03-12 2018-07-06 用於治療細菌感染的殺菌劑與親溶酶體鹼化劑的組合 HK1249033A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15158880 2015-03-12
PCT/EP2016/055076 WO2016142445A2 (en) 2015-03-12 2016-03-10 A method of treatment of a bacterial infection

Publications (1)

Publication Number Publication Date
HK1249033A1 true HK1249033A1 (zh) 2018-10-26

Family

ID=52648929

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108776.3A HK1249033A1 (zh) 2015-03-12 2018-07-06 用於治療細菌感染的殺菌劑與親溶酶體鹼化劑的組合

Country Status (11)

Country Link
US (1) US11690899B2 (zh)
EP (1) EP3268023B1 (zh)
JP (1) JP2018509415A (zh)
CN (1) CN107580503B (zh)
AU (1) AU2016231141B2 (zh)
BR (1) BR112017019413A2 (zh)
CA (1) CA2979873A1 (zh)
HK (1) HK1249033A1 (zh)
IL (1) IL254457B (zh)
SG (1) SG11201707345VA (zh)
WO (1) WO2016142445A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017360064C1 (en) * 2016-11-18 2022-04-07 Lysando Ag New antimicrobial agents against staphylococcus aureus
US20200291373A1 (en) 2017-10-06 2020-09-17 Micreos Human Health B.V. Treatment of a Condition Associated with Infection with an Oncogenic Bacterium
EP3688011A4 (en) * 2017-10-25 2021-11-24 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
US11149068B2 (en) 2018-01-05 2021-10-19 The Administrator Of The Tulane Educational Fund Pore-forming peptides and uses thereof
JP7131803B2 (ja) * 2018-05-15 2022-09-06 学校法人大阪医科薬科大学 Ｇｂ３蓄積起因性疾患の予防又は治療剤
CN109350618B (zh) * 2018-12-10 2021-09-28 山东农业大学 自噬调节剂在消除牛乳腺上皮细胞内金黄色葡萄球菌中的应用
GB201906653D0 (en) * 2019-05-10 2019-06-26 Cc Biotech Ltd Polypeptides for treatment of bacterial infections
CA3171721A1 (en) 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
WO2024020533A1 (en) * 2022-07-22 2024-01-25 Endolytix Technology, Inc. Immunogenic compositions for treating or preventing actinomycetia infections
WO2024133850A1 (en) * 2022-12-23 2024-06-27 Micreos Pharmaceuticals Ag A chimeric endolysin polypeptide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082945A2 (en) * 2000-04-28 2001-11-08 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US20040023897A1 (en) * 2001-11-13 2004-02-05 Caplan Michael J. Methods for preventing or treating disease mediated by toxin-secreting bacteria
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
WO2008076806A2 (en) * 2006-12-15 2008-06-26 Trustees Of Boston University Compositions and methods to potentiate colistin activity
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
AU2010288559B8 (en) 2009-08-24 2015-08-13 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin OBPgpLYS
EP2338916A1 (en) 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
US20140120074A1 (en) 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
DK3085777T3 (da) * 2011-05-04 2020-02-03 Micreos Human Health Bv Polypeptid
US9789167B2 (en) 2012-05-07 2017-10-17 Micreos Human Health B.V. Polypeptide mixes with antibacterial activity
CN104736172A (zh) * 2012-05-09 2015-06-24 康特拉费克特公司 针对革兰氏阳性细菌的噬菌体溶素和抗生素组合
WO2013180316A1 (ko) * 2012-05-29 2013-12-05 주식회사 인트론바이오테크놀로지 박테리오파지 리신 단백질들의 안정성을 개선할 수 있는 조성물
US9206411B2 (en) 2012-06-13 2015-12-08 The United States Of America, As Represented By The Secretary Of Agriculture Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus aureus
EP2679677A1 (en) 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US20160097044A1 (en) 2014-10-01 2016-04-07 The United States Of America, As Represented By The Secretary Of Agriculture Antimicrobial Enzyme Fusions Reduce Resistance and Kill Intracellular Staphylococcus aureus

Also Published As

Publication number Publication date
CN107580503A (zh) 2018-01-12
WO2016142445A3 (en) 2016-11-10
AU2016231141B2 (en) 2022-03-03
CA2979873A1 (en) 2016-09-15
IL254457A0 (en) 2017-11-30
SG11201707345VA (en) 2017-10-30
JP2018509415A (ja) 2018-04-05
US20180271952A1 (en) 2018-09-27
CN107580503B (zh) 2021-07-09
US11690899B2 (en) 2023-07-04
WO2016142445A2 (en) 2016-09-15
AU2016231141A1 (en) 2017-09-28
EP3268023B1 (en) 2021-08-18
BR112017019413A2 (pt) 2018-05-02
EP3268023A2 (en) 2018-01-17
KR20170132201A (ko) 2017-12-01
IL254457B (en) 2020-03-31

Similar Documents

Publication Publication Date Title
HK1249033A1 (zh) 用於治療細菌感染的殺菌劑與親溶酶體鹼化劑的組合
HK1250639A1 (zh) 抗微生物療法
ZA201802719B (en) Treatment compositions providing an antimicrobial benefit
IL270695A (en) catheter
HRP20190580T1 (hr) Kombinirana terapija radi liječenja rezistentnih bakterijskih infekcija
HK1255105A1 (zh) 用於抗微生物治療的經取代苯基噁唑烷酮
SG11201606247QA (en) Antimicrobial inserts for medical devices
EP3263152A4 (en) Medical treatment device
CA186425S (en) Catheter
PL3448992T3 (pl) Środki przeciwdrobnoustrojowe na bakterie Salmonella
SG11202001205PA (en) Anti-occlusion catheter
GB201813876D0 (en) Treatment
ZA201801134B (en) Hydroxytriazine compound and medical use thereof
GB201800546D0 (en) Treatment
PL3497095T3 (pl) Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego
SG11201808307QA (en) Multi-diameter cannula
IL253878A0 (en) An effective substance for the treatment of respiratory inflammation
CA186424S (en) Catheter
GB201807050D0 (en) Medical uses
GB2558090B (en) Prevention and treatment for microbial infections
GB201708650D0 (en) Combination therapy for bacterial infection
GB201814905D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201704949D0 (en) Combination treatment
GB201704303D0 (en) Catheter